Protara Therapeutics, Inc.
NASDAQ:TARABiotechnology
-$0.05 today
- Market cap
- $144.07M
- Beta
- 1.45
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.48
Volume 1.15M
Average 0.73M
TARA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Protara Therapeutics, Inc.NASDAQ: TARA
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $19.54M rose 38.3% year over year, ahead of the +36.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 2.4% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.
Context
- Operating expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +38.3% holds above the trailing-twelve-month pace of +36.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 64.19M USD
- Year-over-year change
- +30.6%
- 4-year CAGR
- +7.8%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 64.19M | +30.6% |
| FY2024 | 2024-12-31 | 49.15M | +13.6% |
| FY2023 | 2023-12-31 | 43.27M | -35.5% |
| FY2022 | 2022-12-31 | 67.06M | +41.2% |
| FY2021 | 2021-12-31 | 47.49M | — |
Operating Expenses vs competitors
How TARA compares with its peers on the latest reported figures
- TARA's LTM Mar 2026 operating expenses of $69.96M is the 6th highest of the 10 companies compared; the peer median is $87.45M.
- Its year-over-year change of +36.0% is the 2nd highest of 9, against a peer median of -5.8%.
- Over three fiscal years its annual growth of -1.4% compares with a peer median of -8.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $144.88M | -0.7% | -22.5% | 419.2% | |
| LTM Mar 2026 | $133.18M | -26.8% | -24.9% | 238.4% | |
| LTM Mar 2026 | $100.47M | -31.6% | -2.4% | 600.9% | |
| LTM Mar 2026 | $91.44M | -11.0% | -9.8% | 117.1% | |
| LTM Mar 2026 | $87.45M | +22.4% | +33.4% | 267.2% | |
| LTM Mar 2026 | $69.96M | +36.0% | -1.4% | — | |
| LTM Mar 2026 | $68.18M | -30.1% | -7.4% | 235.8% | |
| LTM Sep 2026 | $39.45M | +46.4% | -12.9% | — | |
| LTM Mar 2026 | $33.36M | — | — | — | |
| LTM Mar 2026 | $30.87M | +30.6% | +11.1% | 213.2% | |
| Peer median (excluding TARA) | $87.45M | -5.8% | -8.6% | 238.4% | |
Competitors are the stored peer set for TARA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 341K | 0 | 362K |
| Gross Profit | 0 | 0 | (341K) | 0 | (362K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 21.09M | 16.81M | 24.79M | 31.7M | 42.63M |
| Selling, General & Admin | 26.4M | 20.74M | 18.62M | 17.45M | 21.92M |
| Operating Expenses | 47.49M | 67.06M | 43.27M | 49.15M | 64.19M |
| Depreciation & Amortization | 117K | 248K | 341K | 332K | 362K |
| EBITDA | (45.4M) | (64.57M) | (40.08M) | (44.26M) | (57.08M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (47.49M) | (67.06M) | (43.61M) | (49.15M) | (64.55M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 237K | 1.11M | 2.73M | 4.14M | 6.33M |
| Interest Expense | 1.74M | 1.14M | 0 | 0 | 0 |
| Other Income / Expenses | 237K | 1.11M | 3.19M | 4.56M | 7.11M |
| Income Before Tax | (47.25M) | (65.95M) | (40.42M) | (44.6M) | (57.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (47.25M) | (65.95M) | (40.42M) | (44.6M) | (57.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.20) | (5.86) | (3.57) | (2.17) | (1.34) |
| EPS (Diluted) | (4.20) | (5.86) | (3.57) | (2.17) | (1.34) |
| Weighted Avg Shares | 11.23M | 11.26M | 11.33M | 20.59M | 42.84M |
| Weighted Avg Shares (Diluted) | 11.23M | 11.26M | 11.33M | 20.59M | 42.84M |
Protara Therapeutics, Inc.
NASDAQ:TARA
Intrinsic Alpha fair value
Locked
Current Price
$2.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.